Giulia Balconi | Investor
ADJUVANT CAPITAL

Giulia is an investor at Adjuvant Capital, a life science venture capital firm investing in promising technologies for high-burden public health challenges. Giulia has a background in business, finance, and public health. She started her career as an investment banker at J.P. Morgan in London (UK), where she worked in the Technology, Media, and Telecommunications (TMT) team. After her experience in investment banking, she completed a Master of Public Health at UC Berkeley, where she concentrated on healthcare innovations, global health policy, maternal and child health, and vaccination campaigns. After her MPH, she worked at Natera (NASDAQ: NTRA), a biotech company focused on cell-free DNA testing for women’s health, oncology, and organ health. She was also involved in projects in the digital health space, with the startup Cornerstone AI, and in health policy and management research, with UC Berkeley School of Public Health. Giulia graduated with honors from Bocconi University (Italy), where she obtained a BSc in Business Administration and Management and a MSc in International Management.

Appearances:

Pre-Congress Workshops - Monday 30th March @ 10:00

ANTIMICROBIAL RESISTANCE WORKSHOP

Workshop Chair: Dr Christian Harding, CSO and Co-Founder, Omniose

10.00 Chair’s Opening Remarks
10:10 Keynote Intro – Impact of Vaccines on AMR
10.30 Advancing Immunity: Clinical Development of a Peptide Conjugate Vaccine for Group A Streptococcus
10.45 Leveraging Serological Insights to Combat Emerging Pathogens and Antimicrobial Resistance
11.00 The Cost of Inaction: Quantifying the Economic Value of Vaccines in the Fight Against AMR
11.15 Two Targets, One Construct: Psl-PcrV Bioconjugate Vaccine to Tame P. aeruginosa
11.30 AMR, Biodefence and National Security: They’re All Connected
12:00 Mitigating AMR in LMICs: The Role of Vaccines in a One Health World
12.15 Panel Discussion: Perceptions of AMR Vaccine Development in the Current Global Climate
14:00 – 15:00 Funding Pipeline Updates
- 14:00 Gates Foundation
- 14:20 Wellcome Trust
- 14:40 Adjuvant Capital
- 15:00- 16:00 AMR Vaccines Development Updates
  - 15:00 Applying HIV vaccine design principles to Shigella & Acinetobacter
  - 15:15 Universal Pneumococcal Vaccine Development
  - 15:30 From Immunity to Impact: Building Executable Vaccines Against Klebsiella pneumoniae
  - 15:45 Advancing a multivalent vaccine candidate to prevent S.aureus skin infections
16:00 Panel: Are Combination Vaccines the Way Forward for AMR /Defining the Value of Combo Vaccines?
- Economic valuation of vaccines with reduction on AMR
- Improving coverage of viral vaccines which reduce AMR
- Explore the concept of Syndromic vaccines